Head of FDA's diagnostics center, who led through Covid, retires

TimothyStenzelledtheFDA'sdiagnosticsdivisionduringtheCovid-19pandemic,astheagencyscrambledtopushthro 6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid




focus

author：explore    Page View：3523

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

  • Irena Melnikova, Ph.D., partner, Pfizer Ventures
  • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
  • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： There's an unseen cost to disruptive road
Next article： Medicare details structure of new drug price negotiation program